Synergy between BRD9- and IKZF3-Targeting as a Therapeutic Strategy for Multiple MyelomaBasudev Chowdhury(Purdue University West Lafayette), Ellen Weisberg(Dana-Farber Cancer Institute)CancersMarch 28, 202410.3390/cancers16071319Cited by 8SaveCiteExport RISWatch citationsRelated PapersPBRM1 Regulates the Expression of Genes Involved in Metabolism and Cell Adhesion in Renal Clear Cell Carcinoma|PLoS ONE|2016|96Reversible Resistance Induced by FLT3 Inhibition: A Novel Resistance Mechanism in Mutant FLT3-Expressing Cells|PLoS ONE|2011|47Selective Akt Inhibitors Synergize with Tyrosine Kinase Inhibitors and Effectively Override Stroma-Associated Cytoprotection of Mutant FLT3-Positive AML Cells|PLoS ONE|2013|42Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells|Blood|2008|31Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase|Oncotarget|2017|28